Introduction - 27/09/17
Doi : 10.1016/j.amjmed.2017.04.003
Keywords : Cardiovascular, Empagliflozin, EMPA-REG OUTCOME, Sodium glucose cotransporter 2 inhibitors, Type 2 diabetes mellitus
Le texte complet de cet article est disponible en PDF.
| Funding: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. Writing support was provided by Geraldine Thompson of Envision Scientific Solutions, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. The author received no direct compensation related to the development of the manuscript. |
|
| Conflict of Interest: RC has received consulting fees from Boehringer Ingelheim and Eli Lilly and Company. |
|
| Authorship: The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The author was fully responsible for all content and editorial decisions, was involved at all stages of manuscript development, and approved the final version that reflects the author's interpretation and conclusions. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. |
|
| This article is co-published in The American Journal of Medicine (Vol. 130, Issue 6S, June 2017) and The American Journal of Cardiology (Vol. 120, Issue 1S, July 1, 2017). |
© 2017
Publié par Elsevier Masson SAS.
Vol 130 - N° 6S
P. S1-S3 - juin 2017 Retour au numéro
Article précédent
- Table of Contents
- Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
- James Thrasher
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?